Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06794541 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
A Phase 2 study of Complicated Intra-abdominal Infections (cIAI), sponsored by Tetraphase Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 5
- Study locations
NCT06794541: Recruiting Phase 2 study of Complicated Intra-abdominal Infections (cIAI), sponsored by Tetraphase Pharmaceuticals.
NCT06794541 is a Phase 2 study of Complicated Intra-abdominal Infections (cIAI) that is actively recruiting participants, run by Tetraphase Pharmaceuticals. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06794541, a Phase 2 study of Complicated Intra-abdominal Infections (cIAI), is actively recruiting participants, sponsored by Tetraphase Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.
Conditions Studied
Interventions
- DRUG Eravacycline 2mg/kg
- DRUG Eravacycline 1.5mg/kg
Study Locations (5)
California
- UCLA Ronald Reagan University of California Los Angeles Medical Center - Los Angeles
- Children's Hospital of Orange County - Orange
Illinois
- Ann and Robert H Lurie Children's Hospital of Chicago - Chicago
Louisiana
- Children's Hospital of LSU Health Sciences Center Shreveport - Shreveport
West Virginia
- West Virginia University Medicine Children's Hospital - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-05-22 |
| Est. Completion | 2029-03-19 |
| Phase | Phase 2 |
What NCT06794541 shows while recruiting
NCT06794541 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Complicated Intra-abdominal Infections (cIAI) appearing as the primary indexed condition, and to 2 interventions - of which Eravacycline 2mg/kg is the first listed.
NCT06794541 lists 5 locations in 4 states (California, Illinois, Louisiana).
Frequently Asked Questions
What is clinical trial NCT06794541 about?
NCT06794541 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)". A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.
What is the current status of trial NCT06794541?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-05-22. Estimated completion is 2029-03-19.
What conditions does trial NCT06794541 study?
This clinical trial studies the following conditions: Complicated Intra-abdominal Infections (cIAI).
What interventions are being tested in trial NCT06794541?
The interventions under investigation include: Eravacycline 2mg/kg (DRUG), Eravacycline 1.5mg/kg (DRUG).
Who is sponsoring clinical trial NCT06794541?
This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06794541 being conducted?
This trial has 5 study locations across California, Illinois, Louisiana, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06794541's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI